Skip to main content

Alba Maria Jiménez Masip

Institutions of which they are part

Predoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Alba Maria Jiménez Masip

Institutions of which they are part

Predoctoral researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Proyecto de formación integral en enfermedad hepática crónica avanzada

IP: Juan Manuel Pericàs Pulido
Collaborators: Alba Maria Jiménez Masip, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 65000
Reference: CM23/00251
Duration: 02/01/2024 - 01/01/2026

Caracterización de las claves fisiopatológicas y fenotipos de la enfermedad del hígado graso metabólica con ingesta moderada de alcohol para identificar nuevas terapias (ReLiveR).

IP: Meritxell Ventura Cots
Collaborators: Immaculada Raurell Saborit, Juan Manuel Pericàs Pulido, Laura Puente Ramo, Ares Aurora Villagrasa Vilella, Maria de la Serra Cusidó Sabidó, Maria Martínez Gómez, Alba Maria Jiménez Masip
Funding agency: Instituto de Salud Carlos III
Funding: 183920
Reference: PI22/01770
Duration: 01/01/2023 - 31/12/2025

Impacto de la cirugía bariátrica en la hemodinámica portal en pacientes con obesidad mórbida y NAFLD. Estudio HEYMDAL.

IP: Ramón Vilallonga Puy
Collaborators: Mercedes Pérez Lafuente, Nuria Roson Gradaille, Laura Puente Ramo, Marta Comas Martínez, Alba Rojano Toimil, Arturo Cirera De Tudela, Elisa Merino Peña, Clara Pañella Vilamú, Ana Maria Ciscar Bellés, Carlos Petrola Chacón, Alba Maria Jiménez Masip
Funding agency: Instituto de Salud Carlos III
Funding: 171820
Reference: PI22/00880
Duration: 01/01/2023 - 31/12/2025

StopALD

IP: Meritxell Ventura Cots
Collaborators: Alba Maria Jiménez Masip, Juan Manuel Pericàs Pulido, Sonia Carramiñana Mayor
Funding agency: Ajuntament Barcelona
Funding: 119700
Reference: AJUNT.BCN/CIENCIA_INNOV/2022/VENTURA
Duration: 08/12/2022 - 07/06/2024

Related news

The meetings served to share advances in translational research and consolidate international scientific alliances in the study of liver diseases

The consensus establishes recommendations that could correct the current disparities related to muscle mass, weight and height and would allow for more precise prioritization of patients who require transplants more urgently.

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

Related professionals

Cristina Aguilera Martin

Cristina Aguilera Martin

Main researcher
Clinical Pharmacology
Read more
Yolanda Cámara Navarro

Yolanda Cámara Navarro

Main researcher
Neuromuscular and Mitochondrial Pathology
Read more
Ramon Charco Torra

Ramon Charco Torra

Head of group
Hepato-bilio-pancreatic surgery (HBP) and liver transplantation
Read more
Rafael Parra López

Rafael Parra López

Head of group
Transfusional Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.